10-Q: Annovis Bio Faces Going Concern Amid Rising R&D Costs

Annovis Bio reported increased net losses and cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial data and recent capital raises.

Summary

• Annovis Bio, a late-stage clinical drug platform company, is developing buntanetap for Alzheimer's (AD) and Parkinson's (PD) diseases.
• The company reported a net loss of $19.0 million for the nine months ended September 30, 2025, compared to $18.7 million for the same period in 2024.
• Research and development expenses increased to $16.5 million for the nine months ended September 30, 2025, up from $15.0 million in 2024, primarily due to costs for the AD 6-month trial and bioanalytical work.
• General and administrative expenses decreased to $3.5 million for the nine months ended September 30, 2025, from $5.0 million in 2024, mainly due to reduced stock-based compensation and listing fees.
• Cash and cash equivalents stood at $15.3 million as of September 30, 2025, up from $10.6 million at December 31, 2024.
• Net cash used in operating activities increased to $16.7 million for the nine months ended September 30, 2025, from $13.6 million in 2024.
• The company successfully raised $19.3 million net from a February 2025 underwritten offering and $2.2 million gross from an ATM facility during the nine months ended September 30, 2025.
• Subsequent to the reporting period, Annovis Bio secured an additional $5.5 million net from a registered direct offering on October 10, 2025, and $3.1 million net from another registered direct offering and stock subscription agreements on October 26, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, as existing cash is not sufficient to fund operations for one year after the filing date.

Sentiment

Score: 4

Explanation: While clinical trial data shows promise and recent capital raises provide a temporary buffer, the explicit 'going concern' warning, increasing net losses, and high cash burn rate indicate significant financial instability and high risk. The positive clinical updates are overshadowed by the fundamental funding challenges.

Positives

• Positive topline efficacy data from the Phase 3 PD Study showed improvement in UPDRS 2, 3, 2+3 and total in two subgroups, and improved cognition in 12% of patients with cognitive issues.
• Positive topline efficacy data from the Phase 2/3 AD Study showed dose-dependent, statistically significant improvement in ADAS-Cog11 in early AD patients.
• FDA alignment on a clear development path for buntanetap towards New Drug Applications (NDAs) for both short-term and long-term efficacy in AD.
• Initiation of the pivotal Phase 3 AD trial (ANVS-25001) in February 2025, with the symptomatic portion potentially supporting an NDA filing within one year.
• Successful capital raises, including $19.3 million net from a February 2025 offering and an additional $8.6 million net from subsequent offerings in October 2025, bolstering cash reserves.
• Increased interest income to $0.5 million for the nine months ended September 30, 2025, driven by higher cash balances.

Negatives

• Net loss increased to $19.0 million for the nine months ended September 30, 2025, from $18.7 million in the prior year period.
• Accumulated deficit grew to $153.9 million as of September 30, 2025.
• Net cash used in operating activities increased by $3.1 million to $16.7 million for the nine months ended September 30, 2025, indicating a higher cash burn.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, as current cash is insufficient to fund operations for the next 12 months.
• The company continues to rely heavily on equity financings to fund operations and clinical trials, with no committed external sources of funds.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
• Inability to raise additional capital through equity financings, debt, or other alternatives on acceptable terms, or at all.
• Potential need to reduce the scope of, or cease, operations if sufficient additional capital is not raised or operating expenses are not deferred.
• Uncertainty regarding the success of research and development projects and the ability to obtain necessary regulatory approval for product candidates.
• No assurance that any approved product will become commercially viable.
• Operating in an environment of rapid technological change and dependence on employees and consultants.
• Exposure to claims by third parties under various legal disputes, which could materially adversely affect liquidity, financial condition, and cash flows.

Future Outlook

The company expects to incur losses for the foreseeable future, with these losses increasing as it continues development and seeks regulatory approvals for product candidates. It anticipates elevated operating cash burn in 2025 due to costs associated with completing the active Phase 3 trial for AD. The company believes its current cash and cash equivalents will fund operations until the third quarter of 2026, but substantial additional capital will be required to complete development and commercialization, with no assurance of availability on acceptable terms.

Management Comments

• Management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern.
• Management's plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives, and may also include deferral of certain operating expenses.
• We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity.
• Our ultimate goal is to develop a disease modifying drug (DMD) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins.

Industry Context

Annovis Bio operates in the highly challenging neurodegeneration drug development space, targeting Alzheimer's and Parkinson's diseases, which represent significant unmet medical needs in an aging population. The company's approach of inhibiting multiple neurotoxic proteins and aiming to restore axonal and synaptic activity differentiates it from historical industry efforts that often focused on single targets and faced high failure rates. The FDA's engagement and alignment on a development path for buntanetap in AD, including a pivotal Phase 3 trial, indicates a potential pathway forward in an area where successful drug development has been historically difficult.

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that are believed to have a material adverse effect on business, operating results, or financial condition.

Related Party Transactions

• On October 26, 2025, two members of the Board of Directors of the company agreed to purchase an aggregate of 1,073,171 shares of Common Stock through Stock Subscription Agreements as part of a registered direct offering.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from ongoing equity raises; risk of substantial loss if the company cannot secure future funding or if clinical trials fail; potential upside if buntanetap achieves regulatory approval and commercial success.
• **Employees**: Continued employment is contingent on the company's ability to raise capital and continue operations; stock-based compensation is a significant component of overall compensation.
• **Customers (future)**: Potential for new treatment options for Alzheimer's and Parkinson's diseases if buntanetap is successfully developed and approved.
• **Creditors**: Increased risk due to the 'going concern' warning and reliance on equity financing; no significant debt mentioned.
• **Suppliers/CROs**: Continued engagement and payments are dependent on the company's financial health and ability to fund ongoing clinical trials.

Next Steps

• Continue the pivotal ANVS-25001 Phase 3 trial in early AD patients, with a 6-month treatment period for symptomatic efficacy and an additional 12 months for disease-modifying efficacy.
• Potentially file a New Drug Application (NDA) for symptomatic efficacy in AD within one year of the 6-month treatment period initiation, if the trial is well-designed and executed.
• Potentially file a second NDA for disease modification in AD after 18 months, if the long-term portion of the trial is well-designed and executed.
• Conduct an FDA-approved open-label study in PD patients, including previous participants and those with deep brain stimulation (DBS).
• Raise additional capital through equity financings, debt, or other alternatives to fund operations and clinical trials.
• Potentially defer certain operating expenses if additional capital is not secured.

Key Dates

Recommendation

Despite promising clinical trial data for buntanetap in both AD and PD, the explicit 'substantial doubt about the company's ability to continue as a going concern' is a critical red flag. The company's increasing net losses, high cash burn from operations, and continuous reliance on dilutive equity financings to sustain operations present significant financial risk. While recent capital raises provide a short-term buffer, the fundamental issue of long-term funding without a clear path to profitability remains. The stock is highly speculative, and the going concern warning suggests a high probability of further dilution or operational curtailment, making it a 'sell' for risk-averse investors and a 'strong sell' for those prioritizing financial stability.

Keywords

Annovis Bio, buntanetap, Alzheimer's disease, Parkinson's disease, neurodegeneration, Phase 3 trial, clinical stage, biopharmaceutical, SEC filing, 10-Q, going concern, equity offering, cash burn, R&D expenses